Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Oncolytics Bio (ONC.TO)

Oncolytics Bio (ONC.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 127,459
  • Shares Outstanding, K 75,420
  • Annual Sales, $ 0 K
  • Annual Income, $ -27,752 K
  • 60-Month Beta 1.16
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.62
Trade ONC.TO with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.41
  • Most Recent Earnings $-0.05 on N/A
  • Latest Earnings Date 05/09/24 [AMC]
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Biotechnology

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.12
  • Number of Estimates 2
  • High Estimate -0.11
  • Low Estimate -0.12
  • Prior Year -0.10
  • Growth Rate Est. (year over year) -20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.40 +13.57%
on 04/16/24
1.74 -8.62%
on 05/09/24
+0.02 (+1.27%)
since 04/10/24
3-Month
1.22 +30.33%
on 03/04/24
1.75 -9.14%
on 04/04/24
+0.20 (+14.39%)
since 02/09/24
52-Week
1.20 +32.50%
on 02/07/24
4.49 -64.59%
on 06/23/23
-0.60 (-27.40%)
since 05/10/23

Most Recent Stories

More News
Stocks in play: Oncolytics Biotech Inc

Announces recent operational highlights and financial results for the first quarter ended March 31, ...

ONC.TO : 1.59 (-5.92%)
Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced...

ONCY : 1.1700 (-5.65%)
ONC.TO : 1.59 (-5.92%)
Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:ZLAB),(NASDAQ:NTBL),(NASDAQ:CRDF),(NYSE:JNJ) EQNX::TICKER_END

ONCY : 1.1700 (-5.65%)
ONC.TO : 1.59 (-5.92%)
ZLAB : 20.08 (-4.43%)
NTBL : 1.2500 (-15.54%)
CRDF : 3.39 (+0.30%)
JNJ : 149.91 (+0.04%)
Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer

US$5 million PanCAN grant provides important support for the fifth cohort of the GOBLET study   Study of modified FOLFIRINOX/pelareorep/atezolizumab (Tecentriq ® ) combination expands existing pancreatic...

ONCY : 1.1700 (-5.65%)
ONC.TO : 1.59 (-5.92%)
Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

/CNW/ -- In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding...

ONCY : 1.1700 (-5.65%)
CADL : 9.32 (-6.52%)
AZN : 77.18 (-0.55%)
HALO : 43.15 (-1.57%)
JANX : 48.92 (-5.81%)
ONC.TO : 1.59 (-5.92%)
Rising Cancer Rates Drive Biotech Advancements Despite Political Hurdles

USA News Group – In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding for President Biden’s “Cancer...

ONCY : 1.1700 (-5.65%)
ONC.TO : 1.59 (-5.92%)
CADL : 9.32 (-6.52%)
AZN : 77.18 (-0.55%)
HALO : 43.15 (-1.57%)
JANX : 48.92 (-5.81%)
Stocks in play: Oncolytics Biotech Inc.

Will commence enrollment into a new GOBLET study pancreatic cancer cohort following both German regulatory ...

ONC.TO : 1.59 (-5.92%)
Stocks in play: Oncolytics Biotech Inc

Received regulatory clearance to evaluate Pelareorep in combination with modified FOLFIRINOX +/- an ...

ONC.TO : 1.59 (-5.92%)
Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, will commence...

ONCY : 1.1700 (-5.65%)
ONC.TO : 1.59 (-5.92%)
Stocks in play: Oncolytics Biotech Inc

Today announced that Dr. Matt Coffey, President and Chief Executive Officer, will participate in a fireside ...

ONC.TO : 1.59 (-5.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the...

See More

Key Turning Points

3rd Resistance Point 1.77
2nd Resistance Point 1.72
1st Resistance Point 1.65
Last Price 1.59
1st Support Level 1.53
2nd Support Level 1.48
3rd Support Level 1.41

See More

52-Week High 4.49
Fibonacci 61.8% 3.23
Fibonacci 50% 2.84
Fibonacci 38.2% 2.46
Last Price 1.59
52-Week Low 1.20

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar